Nicoxamat

Nicoxamat

SCHEMBL93839

O=C(NO)c1cccnc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 1.00
HDAC6 Q9UBN7 2/20 1.00
THRB P10828 1/20 0.65
LMNA P02545 1/20 0.65
HIF1A Q16665 1/20 0.65
ROCK2 O75116 1/20 0.62
ROCK1 Q13464 1/20 0.62
ALDH1A1 P00352 3/20 0.61
GAA P10253 2/20 0.61
APP P05067 1/20 0.61
HCAR3 P49019 1/20 0.61
HCAR2 Q8TDS4 1/20 0.61
PTGS2 P35354 2/20 0.60
PTGS1 P23219 1/20 0.59
F7 P08709 1/20 0.59
F3 P13726 1/20 0.59
SARM1 Q6SZW1 1/20 0.59
SIRT2 Q8IXJ6 1/20 0.59
SIRT6 Q8N6T7 1/20 0.59
SIRT1 Q96EB6 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nicoxamat SCHEMBL28301679 0.98 HDAC1 (0.96) HDAC1HDAC6THRBLMNAHIF1A
Nicoxamat SCHEMBL29824802 0.88 HDAC1 (0.77) HDAC1HDAC6THRBLMNAHIF1A
SCHEMBL2000041 0.85 HDAC1 (0.74) HDAC1HDAC6THRBLMNAHIF1A
SCHEMBL5361880 0.85 HDAC1 (0.74) HDAC1HDAC6THRBLMNAHIF1A
SCHEMBL27361080 0.83 TSHR (0.72) HDAC1HDAC6THRBLMNAALDH1A1
SCHEMBL6246677 0.82 HDAC1 (0.69) HDAC1HDAC6THRBLMNAHIF1A
Nicotinic Acid Hydrazide SCHEMBL258390 0.82 HDAC1 (0.69) HDAC1HDAC6THRBLMNAHIF1A
SCHEMBL8704315 0.82 HDAC1 (0.69) HDAC1HDAC6THRBLMNAHIF1A
SCHEMBL8162429 0.82 HDAC1 (0.69) HDAC1HDAC6THRBLMNAHIF1A
SCHEMBL10896904 0.82 HDAC1 (0.69) HDAC1HDAC6THRBLMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3455204-B1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC (US) 2025-10-29 EP claimed
WO-2023156070-A1 COSMETIC COMPOSITION THE BOOTS COMPANY PLC (GB) 2023-08-24 WO claimed
WO-2023097386-A1 SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS EUROFARMA LABORATÓRIOS S.A (BR) 2023-06-08 WO claimed
EP-3624804-B1 HISTONE DEACETYLASES (HDACS) INHIBITORS ANNJI PHARM CO LTD (TW) 2022-02-16 EP claimed
US-20220008414-A1 PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2022-01-13 US claimed
US-20200030482-A1 WATER ABSORBENT RESIN COMPOSITION, ABSORBENT, AND ABSORBENT ARTICLE SUMITOMO SEIKA CHEMICALS (JP) 2020-01-30 US claimed
CN-107141244-B Indolebutyric acid class inhibitors of histone deacetylase and its preparation method and application 潍坊医学院 2019-11-19 CN claimed
CN-109153636-A Cyclopropyl-amide compound as dual LSD1/HDAC inhibitor 朱比连特比利斯有限公司 2019-01-04 CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1633334-A2 A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS THE PROCTER & GAMBLE COMPANY (US) 2006-03-15 EP claimed
WO-2005002554-A2 A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS THE PROCTER & GAMBLE COMPANY (US) 2005-01-13 WO claimed
US-20040254202-A1 Method of promoting sleep using topical administration of vasoactive agents THE PROCTER & GAMBLE COMPANY 2004-12-16 US claimed
EP-0896522-B1 METHODS OF REGULATING SKIN APPEARANCE WITH VITAMIN B 3 COMPOUND PROCTER & GAMBLE (US) 2003-10-22 EP claimed
US-20020197289-A1 Compositions and methods for combating the appearance of ageing L'OREAL (FR) 2002-12-26 US claimed
EP-1003751-A1 HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS AMGEN INC. (US) 2000-05-31 EP claimed
WO-1999006410-A1 HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS AMGEN INC. (US) 1999-02-11 WO claimed
WO-1992016200-A1 THE USE OF HYDROXAMIC ACID DERIVATIVES TO INHIBIT VIRAL REPLICATION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) 1992-10-01 WO claimed
EP-0060144-A2 Cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1982-09-15 EP claimed
US-3961064-A LIVER DISORDERS, HEPATITIS EISAI CO., LTD. (JA) 1976-06-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220008414-A1 PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS HDAC6, HDAC1, HDAC3 HDAC1 2/4885HDAC6 1/4885THRB 4045/4885
US-20020197289-A1 Compositions and methods for combating the appearance of ageing CYP24A1, CYP27B1, CYP2R1 HDAC1 2558/4885HDAC6 2101/4885THRB 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.